First Horizon Advisors’s Seres Therapeutics MCRB Stock Holding History

First Horizon Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-45	Closed	-$4.31K	–	2459
2023 Q2	$4.31K	Buy	+45	New	+$4.9K	﹤0.01%	1838
2022 Q3	–	Sell	-14	Closed	-$1K	–	2376
2022 Q2	$1K	Buy	+14	New	+$1.21K	﹤0.01%	2230
2021 Q3	–	Sell	-49	Closed	-$22K	–	2372
2021 Q2	$22K	Buy	49 +16	+48%	+$6.75K	﹤0.01%	1080
2021 Q1	$12K	Buy	+33	New	+$15.2K	﹤0.01%	1239

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

First Horizon Advisors's MCRB Position: Q3 2023 in Review

First Horizon Advisors sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 45 shares — an estimated $4.31K sold.

First Horizon Advisors first reported a position in MCRB in Q1 2021 and held it in 4 quarters. The position peaked at $22K in Q2 2021. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

First Horizon Advisors reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
First Horizon Advisors sold 45 Seres Therapeutics shares in Q3 2023, an estimated $4.31K.
First Horizon Advisors first reported a position in Seres Therapeutics in Q1 2021 and held it in 4 quarters.
First Horizon Advisors's Seres Therapeutics position peaked at $22K in Q2 2021.
134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on First Horizon Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.